Synosia Therapeutics Company
Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.
Connections
Employee Number:
1-10
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Founded Date:
2006-01-01
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Investors:
5AM Ventures, Abingworth, Novo Holdings, Union Chimique Belge, Versant Ventures
Ipo Status:
private
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland